To study DEspR as a potential therapeutic target for PPC, we used multiple blocking anti-DEspR monoclonal antibodies (mAbs) raised against two extracellular domain epitopes of human DEspR (Fig. 1a). Here, FBXW7-AS1 is linked to primary peritoneal carcinoma.